Search

Your search keyword '"Moryusef, Angele"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Moryusef, Angele" Remove constraint Author: "Moryusef, Angele"
21 results on '"Moryusef, Angele"'

Search Results

1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

3. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial

4. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

5. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial

6. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial

7. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

8. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

9. Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy

10. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial†

11. PATIENTS WITH ACUTE CORONARY SYNDROME, ELEVATED ATHEROGENIC LIPOPROTEINS, AND PRIOR CORONARY ARTERY BYPASS GRAFTING DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: INSIGHTS FROM THE ODYSSEY OUTCOMES TRIAL

12. POST-ACUTE CORONARY SYNDROME PATIENTS WITH POLYVASCULAR DISEASE DERIVE LARGE ABSOLUTE BENEFIT FROM ALIROCUMAB: ODYSSEY OUTCOMES

13. Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial

14. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data

15. USE OF HIGH-INTENSITY STATIN THERAPY POST-ACUTE CORONARY SYNDROME IN THE ONGOING ODYSSEY OUTCOMES TRIAL OF ALIROCUMAB, A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 MONOCLONAL ANTIBODY, VERSUS PLACEBO: INTERIM BASELINE DATA

16. REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL

17. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: ameta-analysis of individual patient data.

19. EVALUATION OF THE EFFICACY AND SAFETY OF OTAMIXABAN VS. UNFRACTIONATED HEPARIN+EPTIFIBATIDE IN ELDERLY PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN THE SEPIA-ACS1 TIMI 42 TRIAL

20. Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study

21. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.

Catalog

Books, media, physical & digital resources